1. Home
  2. APLM vs JCTCF Comparison

APLM vs JCTCF Comparison

Compare APLM & JCTCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • JCTCF
  • Stock Information
  • Founded
  • APLM 2016
  • JCTCF 1953
  • Country
  • APLM United States
  • JCTCF United States
  • Employees
  • APLM N/A
  • JCTCF N/A
  • Industry
  • APLM Blank Checks
  • JCTCF RETAIL: Building Materials
  • Sector
  • APLM Finance
  • JCTCF Consumer Discretionary
  • Exchange
  • APLM Nasdaq
  • JCTCF Nasdaq
  • Market Cap
  • APLM 15.6M
  • JCTCF 14.3M
  • IPO Year
  • APLM N/A
  • JCTCF 1996
  • Fundamental
  • Price
  • APLM $0.14
  • JCTCF $4.89
  • Analyst Decision
  • APLM Strong Buy
  • JCTCF
  • Analyst Count
  • APLM 2
  • JCTCF 0
  • Target Price
  • APLM $4.25
  • JCTCF N/A
  • AVG Volume (30 Days)
  • APLM 912.4K
  • JCTCF 6.5K
  • Earning Date
  • APLM 08-14-2024
  • JCTCF 11-26-2024
  • Dividend Yield
  • APLM N/A
  • JCTCF N/A
  • EPS Growth
  • APLM N/A
  • JCTCF N/A
  • EPS
  • APLM N/A
  • JCTCF 0.34
  • Revenue
  • APLM $2,101,000.00
  • JCTCF $48,553,695.00
  • Revenue This Year
  • APLM N/A
  • JCTCF N/A
  • Revenue Next Year
  • APLM N/A
  • JCTCF N/A
  • P/E Ratio
  • APLM N/A
  • JCTCF $14.68
  • Revenue Growth
  • APLM 70.54
  • JCTCF N/A
  • 52 Week Low
  • APLM $0.11
  • JCTCF $3.86
  • 52 Week High
  • APLM $2.24
  • JCTCF $6.35
  • Technical
  • Relative Strength Index (RSI)
  • APLM 45.47
  • JCTCF 57.42
  • Support Level
  • APLM $0.13
  • JCTCF $4.89
  • Resistance Level
  • APLM $0.17
  • JCTCF $4.99
  • Average True Range (ATR)
  • APLM 0.01
  • JCTCF 0.07
  • MACD
  • APLM 0.00
  • JCTCF -0.00
  • Stochastic Oscillator
  • APLM 26.03
  • JCTCF 38.89

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About JCTCF Jewett-Cameron Trading Company

Jewett-Cameron Trading Co Ltd through its subsidiaries engages in the wholesale distribution of a variety of specialty wood products. Its operating segments include, The Industrial wood products segment is engaged in the processing and distribution of industrial wood products. The Pet Fencing and Other segment, which is the key revenue driver, operates as a wholesaler of wood products and a manufacturer and distributor of specialty metal products. The Seed processing and sales segment processes and distributes agricultural seed and Corporate and administrative. The company predominantly operates in United States and also has its presence in Canada, Latin America, Europe and Asia and other regions.

Share on Social Networks: